These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33421321)

  • 1. Contextualizing single-arm trials with real-world data: An emulated target trial comparing therapies for neovascular age-related macular degeneration.
    Thomas DS; Lee AY; Müller PL; Schwartz R; Olvera-Barrios A; Warwick AN; Patel PJ; Heeren TFC; Egan C; Taylor P; Tufail A;
    Clin Transl Sci; 2021 May; 14(3):1166-1175. PubMed ID: 33421321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
    BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Methods of Clinical Trial Emulation Utilizing Data From the Comparison of AMD Treatment Trial (CATT) and the IRIS® Registry.
    Fevrier H; LaPrise A; Mbagwu M; Leng T; Torres AZ; Borkar DS
    Ophthalmol Sci; 2024; 4(5):100524. PubMed ID: 38881608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.
    Arcinue CA; Ma F; Barteselli G; Sharpsten L; Gomez ML; Freeman WR
    Am J Ophthalmol; 2015 Mar; 159(3):426-36.e2. PubMed ID: 25461263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration.
    Talks JS; Lotery AJ; Ghanchi F; Sivaprasad S; Johnston RL; Patel N; McKibbin M; Bailey C; Mahmood S;
    Ophthalmology; 2016 Feb; 123(2):337-343. PubMed ID: 26578446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
    Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
    BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
    Sivaprasad S; Prevost AT; Vasconcelos JC; Riddell A; Murphy C; Kelly J; Bainbridge J; Tudor-Edwards R; Hopkins D; Hykin P;
    Lancet; 2017 Jun; 389(10085):2193-2203. PubMed ID: 28494920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
    Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
    Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
    Wykoff CC; Brown DM; Maldonado ME; Croft DE
    Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in patients receiving fixed-dosed aflibercept for treatment-naïve neovascular age-related macular degeneration during one year of routine clinical practice.
    Oca Lázaro AI; Velilla Osés S; Negredo Bravo LJ
    Arch Soc Esp Oftalmol (Engl Ed); 2019 Sep; 94(9):430-435. PubMed ID: 31182243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
    Ohji M; Takahashi K; Okada AA; Kobayashi M; Matsuda Y; Terano Y;
    Adv Ther; 2020 Mar; 37(3):1173-1187. PubMed ID: 32016788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.